Display options
Cite
Kim HJ, Lee YH, Im SA, et al. Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. Immune Netw. 2010;10(3):92-8doi: 10.4110/in.2010.10.3.92.
Kim, H. J., Lee, Y. H., Im, S. A., Kim, K., & Lee, C. K. (2010). Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. Immune network, 10(3), 92-8. https://doi.org/10.4110/in.2010.10.3.92
Kim, Hyun-Jin, et al. "Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells." Immune network vol. 10,3 (2010): 92-8. doi: https://doi.org/10.4110/in.2010.10.3.92
Kim HJ, Lee YH, Im SA, Kim K, Lee CK. Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. Immune Netw. 2010 Jun;10(3):92-8. doi: 10.4110/in.2010.10.3.92. Epub 2010 Jun 30. PMID: 20631879; PMCID: PMC2902675.
Copy Download .nbib Format: NLM
Share it on

Immune Netw. 2010 Jun;10(3):92-8. doi: 10.4110/in.2010.10.3.92. Epub 2010 Jun 30.

Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells.

Immune network

Hyun-Jin Kim, Young-Hee Lee, Sun-A Im, Kyungjae Kim, Chong-Kil Lee

Affiliations

  1. College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea.

PMID: 20631879 PMCID: PMC2902675 DOI: 10.4110/in.2010.10.3.92

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce fever and inhibit inflammation. NSAIDs function mainly through inhibition of cyclooxygenase (COX). Growing evidence suggests that NSAIDs also have immunomodulatory effects on T and B cells. Here we examined the effects of NSAIDs on the antigen presenting function of dendritic cells (DCs).

METHODS: DCs were cultured in the presence of aspirin or ibuprofen, and then allowed to phagocytose biodegradable microspheres containing ovalbumin (OVA). After washing and fixing, the efficacy of OVA peptide presentation by DCs was evaluated using OVA-specific CD8 and CD4 T cells.

RESULTS: Aspirin and ibuprofen at high concentrations inhibited both MHC class I and class II-restricted presentation of OVA in DCs. In addition, the DCs generated in the presence of low concentrations of the drugs exhibit a profoundly suppressed capability to present MHC-restricted antigens. Aspirin and ibuprofen did not inhibit the phagocytic activity of DCs, the expression level of total MHC molecules and co-stimulatory molecules on DCs. Ibuprofen rather increased the expression level of total MHC molecules and co-stimulatory molecules on DCs.

CONCLUSION: These results demonstrate that aspirin and ibuprofen inhibit the intracellular processing event of the phagocytosed antigen, and further suggest that prolonged administration of NSAIDs in high doses may impair the capability of DCs to present antigens in asiociation with MHC molecules.

Keywords: Antigen processing; Aspirin; Dendritic cell; Ibuprofen

References

  1. Am J Med. 1998 May;104(5):413-21 - PubMed
  2. J Immunol. 1997 Mar 15;158(6):2723-30 - PubMed
  3. J Biol Chem. 2002 Jan 11;277(2):1509-13 - PubMed
  4. Br J Clin Pharmacol. 2002 Mar;53(3):255-65 - PubMed
  5. J Rheumatol. 1997 Aug;24(8):1467-70 - PubMed
  6. Annu Rev Biochem. 2000;69:145-82 - PubMed
  7. Science. 1994 Aug 12;265(5174):956-9 - PubMed
  8. Nature. 1998 Jan 1;391(6662):82-6 - PubMed
  9. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6020-4 - PubMed
  10. J Immunol. 1999 Jul 1;163(1):111-9 - PubMed
  11. Science. 1994 May 13;264(5161):961-5 - PubMed
  12. Nature. 1999 Mar 4;398(6722):77-80 - PubMed
  13. J Cell Biochem. 1995 Feb;57(2):299-310 - PubMed
  14. Annu Rev Immunol. 2001;19:47-64 - PubMed
  15. Adv Immunol. 1996;62:167-215 - PubMed
  16. Mol Pharmacol. 1999 Apr;55(4):625-31 - PubMed
  17. Med Res Rev. 1996 Mar;16(2):181-206 - PubMed
  18. Cell Immunol. 2009;258(1):18-28 - PubMed
  19. Nature. 1998 Nov 5;396(6706):77-80 - PubMed
  20. J Immunol. 2007 Nov 1;179(9):5711-6 - PubMed
  21. J Immunol. 1991 Nov 1;147(9):2860-3 - PubMed
  22. Int Immunopharmacol. 2001 Jul;1(7):1275-84 - PubMed
  23. FASEB J. 2006 Oct;20(12):2009-16 - PubMed
  24. Annu Rev Immunol. 2000;18:767-811 - PubMed
  25. Nat New Biol. 1971 Jun 23;231(25):232-5 - PubMed

Publication Types